Takeda Pharmaceutical Company Ltd (TAK) Noticias

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for...

Form 13F-HR - Quarterly report filed by institutional managers, Holdings

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

CEO Christophe Weber to retire from Takeda in June 2026 after 12 years Julie Kim, president of the U.S. Business Unit, named to succeed Weber...

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

Revenue Growth of +9.8% at Actual Exchange Rates (AER); +4.5% at Constant Exchange Rate (CER) Driven by Strong Momentum of Growth & Launch...

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin...

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June...

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Six Late-Stage Programs with Peak Revenue Potential of $10B - $20B1 Poised to Deliver Sustainable Growth Expected Phase 3 Data Readouts in 2025...

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval...

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone...

Takeda gibt starke Ergebnisse für das erste Halbjahr des Geschäftsjahres 2024 bekannt und erhöht den Ausblick für das Gesamtjahr

Umsatzwachstum von +13,4 % zu aktuellen Wechselkursen (AER); +5,0 % zu konstanten Wechselkursen (CER) Getrieben durch die kontinuierliche...